Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

KMT2C (Lysine Methyltransferase 2C)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

‹

OptiSeq™ Colorectal Cancer Panel

SureSeq™ Pan-Myeloid Panel

OptiSeq™ Colorectal Cancer Panel

SureSeq™ Pan-Myeloid Panel

›

MLL3 mutation + TMB-H	Non Small Cell Lung Cancer	MLL3 mutation + TMB-H	Non Small Cell Lung Cancer	PD1 inhibitor + CTLA4 inhibitor Sensitive: B - Late Trials PD1 inhibitor + CTLA4 inhibitor Sensitive : B	PD1 inhibitor + CTLA4 inhibitor Sensitive: B - Late Trials PD1 inhibitor + CTLA4 inhibitor Sensitive : B
MLL3 mutation + TMB-H	Non Small Cell Lung Cancer	MLL3 mutation + TMB-H	Non Small Cell Lung Cancer	PD-L1 inhibitor Sensitive: B - Late Trials PD-L1 inhibitor Sensitive : B	PD-L1 inhibitor Sensitive: B - Late Trials PD-L1 inhibitor Sensitive : B
KMT2C mutation + TP53 mutation	Non Small Cell Lung Cancer	KMT2C mutation + TP53 mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
MLL3 mutation + TMB-H	Colorectal Cancer	MLL3 mutation + TMB-H	Colorectal Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
KMT2C mutation	Colorectal Cancer	KMT2C mutation	Colorectal Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
KMT2C mutation	Solid Tumor	KMT2C mutation	Solid Tumor	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
KMT2C mutation	Non Small Cell Lung Cancer	KMT2C mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
KMT2C mutation + TMB-H	Colorectal Cancer	KMT2C mutation + TMB-H	Colorectal Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
KMT2C mutation	Hepatocellular Cancer	KMT2C mutation	Hepatocellular Cancer	PD1 inhibitor + lenvatinib Sensitive: C3 – Early Trials PD1 inhibitor + lenvatinib Sensitive : C3	PD1 inhibitor + lenvatinib Sensitive: C3 – Early Trials PD1 inhibitor + lenvatinib Sensitive : C3
KMT2C mutation	Renal Cell Carcinoma	KMT2C mutation	Renal Cell Carcinoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
KMT2C mutation	Melanoma	KMT2C mutation	Melanoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
KMT2C mutation	Bladder Cancer	KMT2C mutation	Bladder Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3